Home › Burkitt Lymphoma › Kentucky
Pag-aaral pangklinika para sa Burkitt Lymphoma sa Kentucky
5 pag-aaral para sa Burkitt Lymphoma ang naghahanap ng mga kalahok sa mga site sa Kentucky.
Mga Lungsod sa Kentucky
Opisyal na teksto ng pag-aaral (English)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
Nagre-recruitPhase 2
366 Days – 46 Years · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
Nagre-recruitPhase 2
365 Days · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06317662Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Kentucky/Markey Cancer Center, Lexington
Nagre-recruitPhase 3
Edad 18 hanggang 39 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT03150693A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
Nagre-recruitPhase 2
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
Nagre-recruitPhase 3
365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.